Immune checkpoint inhibitors for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing how well immune checkpoint inhibitors, which help the body's immune system fight cancer, work in people with advanced liver cancer. The goal is to see if these drugs are effective and safe for patients whose liver is still working reasonably well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have advanced liver cancer (HCC) that has been confirmed by imaging or biopsy
- You should be able to receive immune checkpoint inhibitor therapy (such as atezolizumab-bevacizumab or durvalumab-tremelimumab)
- Your liver function must be preserved, which generally means a Child-Pugh score of A or B (up to 7 points) or a good ALBI score
- You must not have had a liver transplant
- You must not have other active cancers or autoimmune diseases that require strong immune-suppressing medication
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This trial studies how well immunotherapy drugs (atezolizumab and bevacizumab) work for people with advanced liver cancer that cannot be treated with local procedures. It looks at real-life results to see if these treatments help people live longer and feel better.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests whether giving a combination of two immunotherapy drugs before a liver transplant can help people with advanced liver cancer (beyond standard size limits) receive a transplant successfully. The treatment aims to shrink the tumor and improve outcomes.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.